Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin, tislelizumab, and S-1 in HER2-positive advanced gastric cancer
NCT05586061Phase 2Active, not recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Response Rate at 6 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05586061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586061.